Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Most relevant
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASTELLAS PHARMA INC.
2016ASTELLAS PHARMA : Enters a New Collaborative Research Agreement with AIST to Discover Anti..
PU
2016ASTELLAS PHARMA : and LEO Pharma Close Transaction to Transfer Global Dermatology Business..
PU
2016ASTELLAS PHARMA INC : Ex-dividend day for final dividend
FA
2016ASTELLAS PHARMA : and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Lib..
PU
2016ASTELLAS PHARMA : Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone ..
PU
2016ASTELLAS PHARMA : Positive top-line results from phase 3 study evaluating romosozumab in m..
PU
2016ASTELLAS PHARMA : Selected as a Nadeshiko Brand Component for Excellence in Providing Oppo..
PU
2016ASTELLAS PHARMA : Announces Personnel Changes (pdf 47KB)
PU
2016ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 92KB)
PU
2016ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 41KB)
PU
2016ASTELLAS PHARMA : Announces Management Structure Change (pdf 70KB)
PU
2016ASTELLAS PHARMA : Announces Personnel Changes and Organizational Change (pdf 47KB)
PU
2016ASTELLAS PHARMA : Receives Approval for a Supplemental New Drug Application for Kiklin« Ca..
PU
2016ASTELLAS PHARMA : Submits New Drug Application for Linaclotide, Treatment for Irritable Bo..
PU
2016ASTELLAS PHARMA : POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTM..
PU
2016ASTELLAS PHARMA : FDA Accepts For Review Supplemental New Drug Application for XTANDI« (en..
PU
2016ASTELLAS PHARMA : Announces Results of Tender Offer to Acquire All Outstanding Shares of O..
PU
2016ASTELLAS PHARMA : Announces Personnel Changes and Organizational Changes (pdf 57KB)
PU
2016ASTELLAS PHARMA : and CLINO Announce License Agreement to Develop and Commercialize Gene T..
PU
2016ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 139KB)
PU
2016ASTELLAS PHARMA : Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeu..
PU
2016ASTELLAS PHARMA : REPATHA« (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE..
PU
2016ASTELLAS PHARMA : Extension of agreement on Telmisartan (Micardis« family) (pdf 170KB)
PU
2015ASTELLAS PHARMA : Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeu..
PU
2015ASTELLAS PHARMA : Presentation material for Press Conference on December 8 (pdf 1435KB)
PU
2015ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 46KB)
PU
2015ASTELLAS PHARMA : Announces Personnel Change (pdf 46KB)
PU
2015ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 60KB)
PU
2015ASTELLAS PHARMA : and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Co..
PU
2015ASTELLAS PHARMA : Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therap..
PU
2015ASTELLAS PHARMA : Transfers Its Global Dermatology Business to LEO Pharma (pdf 98KB)
PU
2015ASTELLAS PHARMA : Presentation for Astellas to Acquire Ocata Therapeutics (pdf 1512KB)
PU
2015ASTELLAS PHARMA : to Acquire Ocata Therapeutics (pdf 44KB)
PU
2015ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 64KB)
PU
2015ASTELLAS PHARMA : Concludes Agreement with MicroBiopharm Japan on Transfer of Kiyosu Plant..
PU
2015ASTELLAS PHARMA : and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax&t..
PU
2015ASTELLAS PHARMA : Submission of a Supplemental New Drug Application for ASP1585 Granule,a ..
PU
2015ASTELLAS PHARMA : and Chromocell Announce License and Collaboration Agreement to Develop a..
PU
2015ASTELLAS PHARMA INC : Ex-dividend day for interim dividend
FA
2015ASTELLAS PHARMA : Named to FTSE4Good Sustainability Index (pdf 77KB)
PU
2015ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 41KB)
PU
2015ASTELLAS PHARMA : Announces Acquisition of Own Shares
PU
2015ASTELLAS PHARMA : Establishes New Real World Informatics and Analytics Function
PU
2015ASTELLAS PHARMA : Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients wi..
PU
2015ASTELLAS PHARMA : "Cell therapy using human iPSC-derived renal progenitors ameliorates acu..
PU
2015ASTELLAS PHARMA : Initiates Collaborative Research with National Institute of Advanced Ind..
PU
2015ASTELLAS PHARMA : "Cell therapy using human iPSC-derived renal progenitors ameliorates acu..
PU
2015ASTELLAS PHARMA : The Netherlands Decorates Masafumi Nogimori, Representative Director and..
PU
2015ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 201KB)
PU
2015ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 63KB)
PU
2015ASTELLAS PHARMA : Results of Additional Analysis of Data from Japanese Clinical Trial of A..
PU
2015ASTELLAS PHARMA : and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio..
PU
2015ASTELLAS PHARMA : and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio..
BU
2015ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 63KB)
PU
2015ASTELLAS PHARMA : ANNOUNCES PRELIMINARY PHASE 1/2 SAFETY, TOLERABILITY AND EFFICACY DATA F..
PU
2015ASTELLAS PHARMA : Strategic Plan 2015-2017 (pdf 392KB) (pdf 392 KB)
PU
2015ASTELLAS PHARMA : Strategic Plan 2015-2017 (pdf 392 KB)
PU
2015ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 62KB)
PU
2015ASTELLAS PHARMA : Announcement of Approval of Additional Indication for the TNF-a inhibito..
PU
2015ASTELLAS PHARMA : Receives Approval for a Supplemental New Drug Application for Irribow«/I..
PU
2015ASTELLAS PHARMA : AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED AT THE 2015 AMER..
PU
2015ASTELLAS PHARMA : MIRABEGRON AS ADD-ON TREATMENT TO SOLIFENACIN THERAPY DEMONSTRATED SUPER..
PU
2015ASTELLAS PHARMA : Notice Regarding the Introduction of a Performance-linked Stock Compensa..
PU
2015ASTELLAS PHARMA : Announces Cancellation of Treasury Shares (pdf 24KB)
PU
2015ASTELLAS PHARMA : Announces Personnel Change (pdf 62KB)
PU
2015ASTELLAS PHARMA : Announces Consolidated Business Forecasts for Fiscal Year 2014 (pdf 45KB..
PU
2015ASTELLAS PHARMA : Nominates Director and Audit & Supervisory Board Member (pdf 41KB)
PU
2015ASTELLAS PHARMA : The Results of Japanese Clinical Trials of Anti-TNF-alpha Antibody Certo..
PU
2015ASTELLAS PHARMA : and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology..
PU
2015ASTELLAS PHARMA : and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology..
BU
2015ASTELLAS PHARMA : MSD and Astellas sign a memorandum of understanding regarding co-develop..
PU
2015ASTELLAS PHARMA : MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibo..
PU
2015ASTELLAS PHARMA : Celebrates 10th Anniversary
PU
2015ASTELLAS PHARMA INC : Ex-dividend day for final dividend
FA
2015ASTELLAS PHARMA : AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED DURING PLENARY P..
PU
Prev.5  6  7  8  9   10  11  12  13Next
Upcoming event on ASTELLAS PHARMA INC.